{"title": "David A. Bush, MD - Research | Loma Linda University", "author": null, "url": "https://llu.edu/academics/faculty/bush-david/research", "hostname": "llu.edu", "description": null, "sitename": "David A. Bush, MD - Research", "date": "2023-01-01", "cleaned_text": "Research Projects & Grants College/University - Cytogenetic damage as a biomarker of radiation sensitivity in prostate cancer, Role: Co-Investigator, Columbia University, (08/2014 - 07/2015) Status: Closed Federal - ANBL0532: Phase III randomized trial of single vs. tandem myeloablative consolidation therapy for high-risk neuroblastoma, Role: Investigator, Children Oncology Group, (06/2012 - 06/2013) Status: Completed - COG -ANBL0531 Response - and biology-based therapy for intermediate-risk Investigator, Children Oncology - COG Risk-Based Treatment for Non-Rhabdomyosarcoma Sort Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age, Role: Investigator, Children Oncology Group, (03/2023 VAC (VI) patients with intermediate-risk rhabdomyosarcoma Investigator, Children Oncology Group, (04/2022 - 04/2023) Status: Completed - COG # AREN0532 - Treatment for very low, low and standard risk favorable histology Wilms tumor, Role: Investigator, Children intensive cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide (VDC) for patients with high-risk Investigator, Children Group, (08/2008 - 08/2009) Status: Completed - COG phase III randomized trial of gemtuzumab ozogamicin (Mylotarg\u00ae) combined with conventional chemotherapy for de novo acute myeloid leukemia (AML) in children, adolescents, and young adults, Role: Investigator, Children Oncology Group, (06/2011 - 06/2012) Status: Completed - COG AREN0321 - Treatment of high risk renal tumors, Role: Investigator, Children Oncology Group, (11/2013 - 11/2014) Status: Completed - COG - AHOD0431, A Phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin Disease, Role: Investigator, Children Oncology Group, (01/2009 - 01/2010) Status: Completed - COG - ACNS0221 - A phase II study of conformal radiotherapy in patients with low-grade (10/2010 - 10/2011) Status: Completed - COG - AALL00P2, The use of modified BFM +/- compound 506U78 in an intensive chemotherapy regimen for the treatment of T-cell leukemia, Role: Investigator, Children Oncology Group, (03/2005 - 03/2006) Completed - AALL02P2, Treatment of late isolated extramedullary relapse from acute lymphoblastic leukemia (ALL) (Initial Children Oncology Group, (05/2011 - 05/2012) Status: Completed - COG - ACNS0122, A Phase II study to assess the ability of neoadjuvant chemotherapy +/- second look surgery to eliminate all measurable disease prior to radiotherapy for NGGCT, Role: Investigator, Children Oncology Group, (05/2008 - 05/2009) Status: Completed - COG-ACNS0331 - A study evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy (18.00 Gy) and chemotherapy in children with newly diagnosed standard risk medulloblastoma: a Phase III double randomized trial, Role: Investigator, Children Oncology Group, (04/2023 - 04/2024) Status: Approved - COG - AAML03P1 - Treatment of newly diagnosed childhood AML using intensive MRC-based therapy and Gemtuzumab Ozogamicin (GMTZ): A COG pilot Investigator, Children Oncology Group, (10/2008 - 10/2009) Status: Completed - COG - AALL0232 - high risk B - precursor acute Lymphoblastic Leukemia, Role: Investigator, Children Oncology Group, (01/2014 - 01/2015) Status: Completed - COG - ACNS0121 - A Phase II trial of conformal radiation therapy for pediatric patients with localized ependymoma, chemotherapy prior to second surgery for incompletely resected ependymoma and observations for completely 08/2009) Status: Completed - COG-ACNS0126 - A Phase II study of Temozolomide in the treatment of children with high-grade glioma, Role: Investigator, Children Oncology Group, - COG-AALL0031 - A Children's Oncology Group pilot study for the treatment of very high risk Acute Lymphoblastic Leukemia in children and adolescents, Role: Investigator, Children Oncology Group, (04/2008 - 04/2009) Status: COG-AHOD0031-A phase III group-wide study of dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin Disease, Role: Investigator, Children Oncology Group, (12/2010 - 12/2011) Status: Completed - RTOG 96-16: A phase III study of adjuvant chemotherapy after resection for patients with T2N0 stage I non-small cell carcinoma of the lung, Role: PI, National Cancer (07/2008 - therapy for osseous metastases: A study of palliation of symptoms and quality of life, Role: PI, National Cancer Institute/NIH/DHHS, Status: Completed - RTOG 97-08. A phase II study of adjuvant postoperative irradiation combined with cisplatin/taxol chemotherapy following TAH/BSO for patients with high-risk endometrial cancer, Role: Investigator, National Cancer Institute/NIH/DHHS, (12/1998 - 12/1999) Completed - Synchrotron-Based Scanning Research and Biologic Effects Modulated by Various Scanning Techniques, Role: Principal Investigator, Department of Defense, (09/2009 - 10/2013) Status: Closed - Study to Measure Biologic Effects by Proton Scanning Techniques, Role: Principal Investigator, Department of Defense, (09/2007 - 12/2012) Status: Closed - Scanning Proton Beam System for Treating Large and Complex Volumes, Role: PD/PI, United States Army, (09/2007 - 12/2012) Status: Closed - Enhanced Proton Therapy for Adult and Pediatric Cancer Patients Through Development of a Precision Patient Alignment System (PPAS), Role: Principal Investigator, Department of Energy, (09/2006 - 12/2010) Status: Closed - Continuation of synchrotron-based technology enhancement for scanning of breast and lung cancer patients and diagnostic development, Role: Principal Investigator, Department of Defense, (09/2006 - 10/2009) Status: Closed - Development of a helium ion beam research and clinical application platform at LLUMC Proton Beam Treatment Center, Department of Energy, (07/2005 - 07/2008) Status: Closed - Synchroton-based technology enhancement for scanning of breast and lung cancer patients and diagnostic development to modernize synchroton-based proton, Role: PD/PI, Department of Closed - Scanning Protocon Meam System for Treating Large and Complex Volumes, Role: PD/PI, Department of Defense, (07/2002 - 05/2009) Status: Closed For Profit Organization - Bristol-Myers Squibb - CA 184-043: A randomized, double-blind, phase III trial comparing Ipilimumab vs placebo following radiotherapy in subjects with Castration Resistant Prostate Cancer (CRPC) that have received prior treatment with Docetaxel, Role: Investigator, Bristol-Myers Squibb Company, (12/2012 - 12/2013) I/II neoadjuvant study of Capecitabine, Irinotecan, Celecoxib and radiation therapy in patients with locally advanced rectal cancer, Role: Investigator, Pharmacia, (09/2006 - 09/2007) Status: Completed Corp. MK-7339-013-02: Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment- Na\u00efve limited-Stage Small Cell Lung Cancer (LS-SCLC), Role: Sharp & Dohme Corp., (03/2023 - 03/2024) Status: Approved - A phase 3 prospective, randomized, multi-center, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-matched, living donor kidney transplants, Role: Investigator, Medeor Therapeutics, Inc., (05/2023 - 05/2024) Status: Approved - NewLink Genetics Corporation - NLG-0405: A phase III study of chemotherapy and chemoradiotherapy with or without HyperAcute - pancreatic (Algenpantucel-L) immunotherapy with Status: Completed - SWOG R9704: A phase III study of pre and post chemoradiation 5-FU vs pre and post radiation gemcitabine for postoperative treatment of resected bolus injection versus 5-FU by prolonged venous infusion prior to and following combined prolonged venous infusion plus pelvic XRT versus bolus 5-FU plus leucovorin plus levamisole prior to and following combined pelvic XRT plus bolus 5-FU plus leucovorin in patients with rectal cancer, phase II intergroup., Role: Investigator, Southwest Oncology Group, (08/2009 - 08/2010) Status: Completed - trial of transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma, Role: PI, LLU Dept. of Surgery, (07/2020 - 07/2021) Status: Completed - RTOG-0129 - A Phase III trial of concurrent radiation and chemotherapy (followed by surgery for residual primary/N2-3 nodal disease) for advanced head and neck carcinomas, Role: PI, LLU Dept. of Radiation Medicine, (06/2008 - 06/2009) Status: Completed - Phase II trial of lumpectomy and partial breast proton therapy for early stage breast cancer, Role: PI, LLU Dept. of Radiation Medicine, (06/2023 - 06/2024) Status: Approved - Radiation medicine research registry, Role: Investigator, LLU Dept. of Radiation Medicine, (10/2022 - 10/2023) Status: Approved - Comparing long term overall health and well-being outcomes for breast cancer patients treated with proton or conventional radiotherapy, Role: PI, LLU Dept. of Radiation Medicine, (10/2015) Status: Completed - Retrospective study to evaluate the correlation of prostate biopsy findings with extent of disease on MRI examination in patients with prostate cancer, Role: PI, LLU Dept. of Radiation Medicine, (11/2017 - 11/2018) Status: Completed - Phase I-II trial of stereotactic body proton therapy for patients with liver metastases, Role: Investigator, LLU Dept. of Radiation Medicine, (09/2022 - 09/2023) Status: Approved - Phase II trial of partial breast proton therapy for early stage breast cancer with low and intermediate risk factors, Role: PI, LLU Dept. of Radiation Medicine, (08/2023 - 08/2024) Status: Approved - Phase I/II study of combined chemotherapy and high dose, accelerated proton radiation for the treatment of locally advanced non-small cell lung carcinoma, Role: PI, LLU Dept. of Radiation Medicine, (03/2013 - 03/2014) Status: Completed - Phase I/II study of proton beam therapy for hepatocellular carcinoma, Role: PI, LLU Dept. of Radiation RTOG supretentorial malignant glioma, LLU Dept. of Radiation Medicine, - 10/1999) Status: Completed Non-Profit Organization - RTOG 91-11. Phase III Trial to Preserve the Larynx: Induction Chemotherapy and Radiation Therapy Vs Concomitant Chemotherapy and Radiation Therapy Vs Radiation Therapy, Role: PI, Radiation Therapy Oncology Group, (01/2008 - 01/2009) Status: Completed - National Surgical adjuvant breast and bowel project (NSABP) R-04 a clinical trial comparing preoperative radiation therapy and capecitabine with or with out oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (05/2014 - 05/2015) Status: Completed - NSABP-B-38 - A Phase III, adjuvant trial comparing three chemotherapy regiments in women with node-positive breast cancer: docetaxel/doxorubicin/cyclophosphamide (TAC); dose-dense (DD) doxorubicin/cyclophosphamide followed by DD paclitaxel (DD AC P); DD AC followed by DD paclitaxel plus gemcitabine (DD AC PG), Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2015 - 11/2016) Status: Completed - NSABP-B-36 - A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (08/2015 - 08/2016) Status: Completed - RTOG-0122 - A double-blind study of nutritional intervention for the treatment of cancer cachexia using Juven nutritional supplement, Role: PI, Radiation Therapy Oncology Group, (07/2004 - 07/2005) Status: Completed - RTOG-BR-0119 - A randomized Phase II study of A.M. and P.M. melatonin for brain metastasis in RPA Class II patients, Role: PI, Radiation Therapy Oncology Group, Status: Completed - RTOG-GO114 - A randomized phase II comparison of two cisplatin-paclitaxel containing chemoradiation regimens in resected gastric cancers, Therapy Oncology Group, (08/2008 - 08/2009) Status: Completed - A prospective comparative study of outcomes with proton and photon radiation in prostate cancer (COMPPARE), Role: Outcomes Institute (PCORI), Status: Approved - RTOG-PA-0020 - A Randomized Phase II Trial of weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Transferase Inhibitor R115777 (NSC #702818) Locally Radiation Therapy Oncology Group, Status: Completed - RTOG-R0012 Randomized phase II trial preoperative combined modality chemoradiation for distal rectal cancer, (04/2008 - 04/2009) Status: Completed - NSABP B43: A phase III clinical trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-positive ductal carcinoma in situ resected by lumpectomy, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (02/2023 - 02/2024) Status: Approved - RTOG-9809 - Phase III study of pentosanpolysulfate (PPS) in treatment of GI tract sequelae of radiotherapy, Role: PI, Radiation Therapy Oncology Group, Status: Completed - RTOG 9812. A phase II study of external irradiation (50.4 Gy) and weekly paclitaxel (taxol) for non-metastatic Group, Status: Completed - RTOG-9811. A phase III mitomycin-C, and radiotherapy versus 5-fluorouracil, radiotherapy in of the anal canal, PI, Radiation Therapy Oncology Group, (03/2008 - 03/2009) Status: Completed - RTOG-9709. A phase III study to test the efficacy of the prophylactic use of oral pilocarpine to reduce hyposalivation and mucositis associated with curative radiation therapy in head and neck cancer patients., Role: PI, Radiation Therapy Oncology Group, (11/1999 - 11/2000) Status: Completed - RTOG 9704 - A phase III study of pre and post chemoradiation 5-FU vs pre and post chemoradiation of Completed - RTOG 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck, Role: PI, Radiation Therapy Oncology Group, (03/2008 - bolus injection versus 5-FU by prolonged venous infusion prior to and following combined prolonged venous infustionn plus pelvic XRT versus bolus 5-FU plus leucovorin plus levamisole prior to and following combined pelvic XRT plus bolus 5-FU plus leucovorin in patients with rectal cancer, phase III intergroup, Role: PI, Radiation Therapy Oncology Group, (08/1999 - 08/2000) Status: Completed - RTOG 9514. A phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall, Role: PI, Radiation Therapy Oncology Group, (03/1999 - 03/2000) Status: Completed - RTOG 86-10 III Study of Zoladex and Flutamide used as cytoreductive agents in locally advanced carcinoma of the prostate treated with definitive radiotherapy, Role: PI, Radiation Therapy Oncology Group, (12/2007 - 12/2008) Status: Completed - RTOG-9410. A three-arm phase III study of concomitant versus sequential chemotherapy and thoracic radiotherapy for patients with locally advanced inoperable non-small cell lung cancer, Role: PI, Radiation Therapy Oncology Group, (04/2008 - 04/2009) Status: Completed - RTOG-9914 A phase II trial of concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas, Role: PI, Radiation Therapy Oncology Group, (08/2000 - 08/2001) Status: Completed - NSABP-B31 - A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol (AC-T) to that followed by taxol plus herceptin (AC-T+HC) in node-positive breast cancer patients who have tumors that overexpress HER2., Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (12/2019 - 12/2020) Status: Completed - RTOG 90-03. A Phase III Randomized Study to Compare Twice Daily Hyperfractionation, Accelerated Hyperfractionation with a Split and Accelerated Fractionation with Concomitant Boost to Standard Fractionation Radiotherapy for Squamous Cell Carcinomas of the Head and Neck, Role: PI, Radiation Therapy Oncology Group, (01/2008 - 01/2009) Status: Completed - RTOG 87-04. A Phase II Randomized Study Employing 5 Fluorouracil and Radiotherapy vs 5 Fluorouracil, Mitomycin-C and Radiotherapy in Carcinoma of the Anal Canal, Role: PI, Radiation Therapy Oncology Group, (11/2007 - 11/2008) Status: Completed - RTOG 85-31. Phase III Study of Zoladex Adjuvant to Radiotherapy in Unfavorable Prognosis Carcinoma of the Prostate, Role: PI, Radiation Therapy Oncology Group, (04/2003 - 03/2004) Status: Completed "}